What is it?
Coenzyme Q10 (CoQ10) is also called ubiquinone, a name that signifies its ubiquitous
(widespread) distribution in the human body. CoQ10 is used by the body to transform food into
adenosine triphosphate (ATP), the energy on which the body runs.
CoQ10 is a powerful antioxidant that
protects the body from free radicals1 and helps preserve vitamin E, the major antioxidant of cell membranes and
blood cholesterol.2
CoQ10 supplementation has been investigated as a way to improve physical endurance because
of its effect on energy production; however, most research shows that CoQ10 does not improve
athletic performance.3 In other
research, investigators reported no differences in CoQ10 in muscles or blood from patients
with fibromyalgia compared with healthy
people.4
Synthesis of sperm requires considerable energy. Due to its role in energy production,
CoQ10 has been studied in infertile men.
Preliminary research reports that supplementation of CoQ7, a related molecule, increased sperm
counts in a group of infertile men.5
Healing of the gums of the mouth (periodontal tissue) may require increased energy
production; therefore, researchers have explored the effects of CoQ10 supplementation in
people with periodontal disease, which has
been linked to CoQ10 deficiency. Double-blind research shows that people with gum disease
given CoQ10 achieve better results than those given a placebo.6
The role of CoQ10 in energy formation also relates to how the body uses carbohydrates.
Preliminary research suggests that a close relative of this nutrient lowered blood sugar
levels in a group of people with
diabetes.7 People with type 2 (adult onset) diabetes have been found to have
significantly lower blood levels of CoQ10 compared with healthy people.8
Virtually every cell of the human body contains CoQ10. It is concentrated in the
mitochondria, the area of cells where energy is produced. The heart and liver contain the
greatest amount of CoQ10. It has helped some people with congestive heart failure,(CHF)9 an effect
reported in an analysis of eight controlled trials10 and found in
some,11 though not all, double-blind studies.12 13
14 The beneficial effects of CoQ10 may not be seen until after several months of
treatment. Discontinuation of CoQ10 supplementation in people with CHF has resulted in severe
relapses and should only be attempted under the supervision of a doctor.15
Similar improvements have been reported in people with cardiomyopathies—a group of diseases affecting
heart muscle. Research (including double-blind studies) in this area has been consistently
positive.16
Also, due to its effect on heart muscle, researchers have studied CoQ10 in people with heart arrhythmias. Preliminary research in this
area reported improvement after approximately one month in people with premature ventricular
beats (a form of arrhythmia) who also suffer from
diabetes.17
Angina patients taking 150 mg per day of
CoQ10 report a greater ability to exercise without experiencing chest pain.18 This
has been confirmed in independent investigations.19
CoQ10 appears to increase the heart’s tolerance to a lack of oxygen. Perhaps as a
result, preliminary research has shown that problems resulting from heart surgery occurred
less frequently in people given CoQ10 compared with the control group.20
Muscle mitochondria lack adequate CoQ10 in people with muscular dystrophy, a problem that
could affect muscle function. In a double-blind three-month trial, four of eight people with
muscular dystrophy had improvements in heart function and sense of well-being when
supplementing CoQ10.21
Mitochondrial function also appears to be impaired in people with Alzheimer’s disease. Due to CoQ10’s
effects on mitochondrial functioning, one group of researchers has given CoQ10 (along with iron and vitamin B6) to several people with Alzheimer’s
disease and reported the progression of the disease appeared to have been prevented for one
and a half to two years.22
CoQ10 also modulates immunity.23
Perhaps as a result, a few cases have been reported in which women with metastatic breast cancer (cancer that had spread to other
tissues) had a regression of their cancer
after treatment with a very large amount of CoQ10 (390 mg per day).24
CoQ10 appears to modulate blood pressure by reducing resistance to blood flow.25
Several trials have reported that supplementation with CoQ10 significantly reduced blood
pressure in people with hypertension, usually
after ten weeks to four or more months of treatment.26
In a double-blind study of 21 patients with chronic renal (kidney) failure, 15 of whom were
on dialysis, supplementation with 60 mg of CoQ10 three times per day for four weeks improved
certain measures of kidney function (BUN [blood urea nitrogen], serum creatinine, and
creatinine clearance), compared with placebo, and eliminated the need for dialysis in some
patients.27 Because chronic renal failure is a serious and complicated disease,
individuals with this condition should take CoQ10 only under strict medical supervision.
In a double-blind trial, administration of 1,200 mg of CoQ10 per day for 16 months to
people with early Parkinson’s disease significantly slowed the progression of the
disease, compared with a placebo.28 Smaller amount of CoQ10 were slightly more
effective than placebo, but the difference was not statistically significant.
1. Weber C, Jakobsen TS, Mortensen SA, et al. Antioxidative effect of
dietary coenzyme Q10 in human blood plasma. Int J Vitam Nutr Res 1994;64:311-5.
2. Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by
ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Mol Aspects Med
1997;18:S85-103.
3. Kelly GS. Sport nutrition: a review of selected nutritional
supplements for endurance athletes. Altern Med Rev 1997;2:282-95.
4. Thorsteindottir B, Rafnsdottir S, Geirsson AJ, et al. No difference in
ubiquinone concentration of muscles and blood in fibromyalgia patients and healthy controls.
Clin Exp Rheumatol 1998;16:513-4.
5. Tanimura J. Studies on arginine in human semen. Part III. The
influences of several drugs on male infertility. Bull Osaka Med School
1967;12:90-100.
6. Gaby AR. Coenzyme Q10. In A Textbook of Natural Medicine, by
Pizzorno JE, Murray MT. Seattle: Bastyr University Press, 1998, V:CoQ10-1-8. [review].
7. Shigeta Y, Izumi K, Abe H. Effect of coenzyme Q7 treatment on blood
sugar and ketone bodies of diabetics. J Vitaminol 1966;12:293-8.
8. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment of
3-hydroxy-3-methylglutaryl coenzyme I reductase inhibitors on serum coenzyme Q10 in diabetic
patients. Arzneimittelforschung 1999;49:324-9.
9. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term
coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure.
Drug Exptl Clin Res 1985;11:581-93.
10. Soja AM, Mortensen SA. Treatment of chronic cardiac insufficiency
with coenzyme Q10, results of meta-analysis in controlled clinical trials. Ugeskr
Laeger 1997;159:7302-8.
11. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 in
patients with congestive heart failure: a long-term multicenter randomized study. Clin
Investig 1993;71:S134-6.
12. Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in
the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J
1992;13:1528-33.
13. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme
Q on left ventricular function in patients with congestive heart failure. J Am Coll
Cardiol 1999;33:1549-52.
14. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme
Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-40.
15. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term
coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure.
Drug Exptl Clin Res 1985;11:581-93.
16. Gaby AR. The role of coenzyme Q10 in clinical medicine: part II.
Cardiovascular disease, hypertension, diabetes mellitus and infertility. Altern Med
Rev 1996;1:168-75 [review].
17. Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac
arrhythmias using a 24-hour continuous electrocardiographic recorder (5th
report)—antiarrhythmic action of coenzyme Q10 in diabetics. Tohoku J Exp Med
1983;141(suppl):453-63.
18. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10
on exercise tolerance in chronic stable angina pectoris. Am J Cardiol
1985;56:247.
19. Mortensen SA. Perspectives on therapy of cardiovascular diseases with
coenzyme Q10 (ubiquinone). Clin Invesigt 1993;71:S116-23 [review].
20. Tanaka J, Tominaga R, Yoshitoshi M, et al. Coenzyme Q10: the
prophylactic effect on low cardiac output following cardiac valve replacement. Ann Thorac
Surg 1982;33:145-51.
21. Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and
the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc
Natl Acad Sci 1985;82:4513-6.
22. Imagawa M, Naruse S, Tsuji S, et al. Coenzyme Q10, iron, and vitamin
B6 in genetically-confirmed Alzheimer’s disease. Lancet 1992;340:671
[letter].
23. Folkers K, Shizukuishi S, Takemura K, et al. Increase in levels of
IgG in serum of patients treated with coenzyme Q10. Res Commun Pathol Pharmacol
1982;38:335-8.
24. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy
of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res
Commun 1995;212:172-7.
25. Digiesi V, Cantini F, Bisi G, et al. Mechanism of action of coenzyme
Q10 in essential hypertension. Curr Ther Res 1992;51:668-72.
26. Gaby AR. The role of coenzyme Q10 in clinical medicine: part II.
Cardiovascular disease, hypertension, diabetes mellitus and infertility. Altern Med
Rev 1996;1:168-75 [review].
27. Singh RB, Khanna HK, Niaz MA. Randomized, double-blind
placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role.
J Nutr Environ Med 2000;10:281-8.
28. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in
early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol
2002;59:1541–50.
29. Artuch R, Vilaseca MA, Moreno J, et al. Decreased serum ubiquinone-10
concentrations in phenylketonuria. Am J Clin Nutr 1999;70:892–5.
30. Weiss M, Mortensen SA, Rassig MR, et al. Bioavailability of four oral
coenzyme Q10 formulations in healthy volunteers. Molec Aspects Med
1994;15:273–80.
31. Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E, et al. Effect of oral
coenzyme Q10 on the oxidation resistance of human VLDL + LDL fraction: absorption and
antioxidative properties of oil and granule-based preparations. Free Radic Biol Med
1997;22:1195–202.
32. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative
bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res
1998;68:109–13.
33. Larsson O. Effects of isoprenoids on growth of normal human mammary
epithelial cells and breast cancer cells in vitro. Anticancer Res
1994;114:123–8.
34. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression
of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res
Commun 1994;199:1504–8.
35. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy
of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res
Commun 1995;212:172–7.
36. Judy WV. Nutritional intervention in cancer prevention and treatment.
American College for Advancement in Medicine Spring Conference, Ft. Lauderdale, FL. May 3,
1998.